Julian Adams
Independent Chairman & Member of Scientific Advisory BoardDr. Julian Adams, Ph.D., serves as Member of Scientific Advisory Board at Nucleai Inc. since November 2022. He serves as the Independent Chairman of Elicio Therapeutics Inc. since January 9, 2017 and serves as its Member of Scientific Advisory Board. He served as Executive Chairman of Elicio Therapeutics Inc. He served as the Chief Executive Officer of Gamida Cell Ltd. since November 20, 2017 until September 2022. Dr. Adams was the President and Chief Science Officer at Clal Biotechnology Industries Ltd. since January 23, 2017 until 2019. He served as a Scientific Adviser at Clal Biotechnology Industries Ltd. since 2019 until 2019. He serves as a Scientific Advisor at the firm. He served as the President of Research & Development at Infinity Pharmaceuticals, Inc. from 2003 to January 6, 2017. He served Senior Vice President of Research & Development at Infinity Pharmaceuticals, Inc. since October 2003 and also served as its Chief Scientific Officer from September 2006 to May 2010. From December 1999 to October 2003, he served as a Senior Vice President of Drug Discovery & Development at Millenium Pharmaceuticals., a subsidiary of the biopharmaceutical company Takeda Pharmaceutical Company Limited since 2008 where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program. He joined Millennium Pharmaceuticals in December of 1999 following the Millennium's merger with LeukoSite Inc., where he served as a Senior Vice President of Research and Development. From 1994 to 1999, he served as an Executive Vice President of Research and Development at Proscript Inc. In 1987, he joined Boehringer Ingelheim, where he served in various senior positions in research and development including Director of Medicinal Chemistry. At the firm he was credited with the discovery of Viramune® (nevirapine) for HIV. He served as Senior Vice President of Clinical Development and Med at Cytomed, Inc. He served as the President of Infinity Pharmaceuticals, Inc. from September 2006 to October 2007. From 1982 to 1987, he served as a Medicinal Chemist of Merck in Montreal. He was the Chairman of Gamida Cell Ltd. since November, 2016 until September 18, 2018 and its Director since August 2016 until 2024 also its Executive Chairman. He serves as an Executive Chairman and a Board Member at Curetech. He served as Chairman at CureTech Ltd. since May 14, 2017 until October 22, 2017. He was a Director of Pieris Pharmaceuticals, Inc. from July 25, 2016 until July 25, 2018 and serves as Director of Warp Drive Bio, LLC since July 2013. He has been a Member of Scientific Advisory Board at REVOLUTION Medicines, Inc. since December 13, 2016 and serves as its Senior Advisor. He serves as a Member of Scientific Advisory Board at Mediphase Venture Partners and Raze Therapeutics, Inc., Cleave Biosciences and Stand Up to Cancer. He served as Director of Neon Therapeutics Inc. since December 2017 until August 28, 2018. He served as a Director of Predix Pharmaceuticals, Inc. He served as Member of Advisory Board at Cytomed, Inc. He served as a Director of Predix Pharmaceuticals Holdings Inc. since September 2003 and Aileron Therapeutics Inc. since May 2011. He served as a Member of Scientific Advisory Board at BIND Therapeutics, Inc. since May 2011. He served as a Member of Scientific Advisory Board at DNIB Unwind, Inc., Sirtris Pharmaceuticals, Inc., Verastem, Inc. and Constellation Pharmaceuticals, Inc. He has been integrally involved in the discovery and development of a marketed drug Velcade. He is an Editor of a book on The Proteasome in Cancer. Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an Inventor on more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. Dr. Adams has experience in drug discovery and development with a strong focus on cancer, oncology. Dr. Adams holds a PhD from the Massachusetts Institute of Technology in the field of Synthetic Organic Chemistry and a BS from the McGill University. Dr. Adams also received a Doctor of Science, honoris causa, from McGill University in 2012.
Positions
- Company NameElicio Therapeutics, Inc.Stock CodeELTXPositionIndependent Chairman & Member of Scientific Advisory BoardColleagues
- RTRobert T. ConnellyCEO, President & Director
- ARAllen Richard NissensonFounder & Independent Director
- PSPreetam ShahChief Strategy & Financial Officer and Treasurer
- CMChristopher M. HaqqExecutive VP, Head of Research & Development and Chief Medical Officer
- DJDarrell J. IrvineCo-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board
- CGCarol Gail AsheIndependent Director
